April 12, 2020 – The human genetic disease neurofibromatosis type 1 (NF-1) is a complex multi-system disorder caused by the mutation of a gene  (NF1 gene) on chromosome 17 that is responsible for production of a protein called neurofibromin which is …

First therapy for children with debilitating NF-1 approved in the USA Read more »

Tagged with: , , , , , , , , , , , , , , ,

March 25, 2020 – The Covid-19 pandemic keeps the word abreast. Drastic measures have been and are being taken worldwide by governments, hospitals, healthcare  care providers, and retiring homes in attempts to halt the spreading of Covid-19 disease. Recently, there have …

Covid-19 disease: Be careful with chloroquine and hydroxychloroquine Read more »

Tagged with: , , , , , , , , , , ,

March 10, 2020 – A widespread assumption is, the people of Asian descent are more prone to serious, sometimes deadly adverse drug reactions, even when taking rather common medications prescribed for gout through to depression. In the ages of genetics …

Are Asians at higher genetic risk of serious adverse events to common medications? Read more »

Tagged with: , , , , , , , , , , , , , ,

February 26, 2020 – Fragile X syndrome (FXS) is a genetic disorder characterized by mild-to-moderate intellectual disability.The average IQ in males is under 55, while about two thirds of females are intellectually disabled. Physical features may include a long and narrow …

The first genetic test to aid in the diagnosis of Fragile X Syndrome Read more »

Tagged with: , , , , , , , , , ,

August 13, 2019 – Onasemnogene abeparvovec-xioi (Zolgensma) is an adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 …

Onasemnogene abeparvovec-xioi (Zolgensma): Approval strategy with manipulated data? Read more »

Tagged with: , , , , , , , ,

May 30, 2019 – The American Food and Drug Administration (FDA) recently approved Alpelisib (Piqray) to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor …

The PI3K inhibitor Alpelisib (Piqray) for progressing breast cancer in women (and men) Read more »

Tagged with: , , , , , , , , , , , , ,

May 29, 2019 – Spinal muscular atrophy (SMA) is a group of neuromuscular disorders that result in the loss of motor neurons and progressive muscle wasting. The severity of symptoms and age of onset varies by the type. Some types are apparent at …

Gene therapy: Zolgensma to treat spinal muscular atrophy Read more »

Tagged with: , , , , , , , , , ,

19 April 2019 – Alemtuzumab (Lemtrada) is used in the treatment of multiple sclerosis (MS). Moreover, Alemtuzumab, under the Tradenames of Campt, MabCampath and Campt-1H is on the markets for the treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL), and T-cell …

Lemtrada: Deleterious unwanted effects in some multiple sclerosis patients Read more »

Tagged with: , , , , , , ,

April 07, 2019 – Consumers are increasingly embracing genetic testing to better understand their individual risk for developing diseases. With this rise in popularity and availability, we’re also seeing significant activity in the field of pharmacogenetics, which is the process …

Genomics lab illegally markets genetic tests that claim to predict patient responses to drugs Read more »

Tagged with: , , , , , , , ,

March 31, 2019 – The American Food and Drug Administration (FDA) has just approved  drugs for two rather problematic neurological conditions, namely multiple sclerosis (i.e., Cladribine (Mavenclad)) and non-radiographic axial spondyloarthritis (i.e., Certolizumab pegol (Cimzia)), offering patients with these conditions …

New treatments for multiple sclerosis and inflammatory arthritis approved Read more »

Tagged with: , , , , , , , ,